A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs TTI 621 (Primary)
- Indications Mycosis fungoides; Solid tumours
- Focus Adverse reactions
- Sponsors Trillium Therapeutics
- 25 Jan 2018 Planned number of patients changed from 54 to 240.
- 11 Aug 2017 According to a Trillium Therapeutics media release, preliminary data expected in the second half of 2017.
- 22 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.